New biosimilar aims to offer cheaper eczema treatment

NCT ID NCT07358156

Recruiting now Disease control Sponsor: Chong Kun Dang Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called CKD-706, which is a biosimilar (a close copy) of the approved eczema treatment Dupixent. The study involves 519 healthy adults who will receive a single injection of either CKD-706, the US version of Dupixent, or the European version. Researchers will compare how the drugs move through the body and check for side effects, but this study does not test whether the drug actually improves eczema symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CKD-706 (a biosimilar to Dupixent)
What this could lead to: If successful, this could lead to a more affordable treatment option for atopic dermatitis, similar to Dupixent.
What could go wrong: This is an early Phase 1 study in healthy people, not patients. It only tests a single dose, so it cannot show if the drug actually treats the disease. The biosimilar may not work as well as the original.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Parexel EPCU Berlin
NOT_YET_RECRUITING

Berlin, State of Berlin, 10115, Germany
Parexel EPCU London
RECRUITING

London, England, HA1 3UJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.